Vertex Pharmaceuticals Inc. diskutieren

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Wells Fargo & Company from $555.00 to $460.00. They now have an "overweight" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Piper Sandler from $535.00 to $533.00. They now have an "overweight" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $535.00 to $550.00. They now have a "buy" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "outperform" rating re-affirmed by analysts at William Blair.

Alright, folks, let's talk Vertex Pharmaceuticals! I'm pretty jazzed about this one. They just got the FDA's thumbs up for Journavx, their new non-opioid painkiller. This is huge! It's like they've struck gold in the pain management market. Think about it - a non-addictive alternative to opioids? That's a game-changer. The stock's already riding high on this news, and I think it's got more room to grow. Sure, some analysts are playing it cool, worried about the lack of big catalysts on the horizon. But come on, isn't revolutionizing pain treatment catalyst enough? Plus, with their strong position in cystic fibrosis treatments, Vertex isn't a one-trick pony. Yeah, they might need to beef up their pipeline, but with Journavx potentially bringing in billions, they'll have the cash to do just that. It's not all smooth sailing, and there are always risks in pharma. But in my book, Vertex is looking pretty sweet right now. It's like they're surfing a wave of innovation, and I think they're gonna ride it far.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $550.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Truist Financial Co. from $460.00 to $520.00. They now have a "buy" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Bank of America Co. from $555.00 to $567.00. They now have a "buy" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $535.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $535.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $512.00 to $515.00. They now have an "overweight" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "outperform" rating re-affirmed by analysts at William Blair.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at The Goldman Sachs Group, Inc..

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $550.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $515.00 to $517.00. They now have an "overweight" rating on the stock.